{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/66ba1fa13889f01ccfc72472/66fff4753b7964bedebd57ad?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Les ruptures technologiques - Chapitre 4 : CAR-T","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/66ba1fa13889f01ccfc72472/1728050230427-022fbd64-9a62-4403-bbda-8519fcc38592.jpeg?height=200","description":"<h2>Chapitre 4 – Les exploits des Cellules CAR-T</h2><p><br></p><ul><li>Cellules CAR-T, de véritables \"médicaments vivants\"</li><li>CAR-T Cells dans le combat contre le cancer</li><li>Vers le traitement personnalisé</li><li><br></li></ul><blockquote>Avec <strong>Nabil Lounis</strong><em>– senior Associate Scientist chez Sanofi –</em> et <strong>Christophe Ferrand</strong> <em>– Directeur de recherche INSERM (UMR1098 RIGHT) , cofondateur de Advesya (ex CanCell Therapeutics).</em></blockquote>","author_name":"Ozyme"}